Cabaletta Bio Inc reports results for the quarter ended June 30 - Earnings Summary

• Cabaletta Bio Inc CABA reported a quarterly adjusted loss of 73 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -56 cents. The mean expectation of ten analysts for the quarter was for a loss of 65 cents per share. Wall Street expected results to range from -76 cents to -11 cents per share.

• Reported revenue was zero​; analysts expected $4.17 million.

• Cabaletta Bio Inc's reported EPS for the quarter was a loss of 73 cents​.

• The company reported a quarterly loss of $45.13 million.

• Cabaletta Bio Inc shares had fallen by 4.6% this quarter and lost 36.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 14.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Cabaletta Bio Inc is $15.00, about 90.3% above its last closing price of $1.45

This summary was machine generated from LSEG data August 7 at 05:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)